Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor + G-CSF for Stem Cell Mobilization in Japanese NHL Patients
NCT02221492Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of plerixafor in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Sanofi. Primary endpoint: Proportion of participants who achieve a collection of greater than or equal to 5 x10^6 cells/kg CD34+ cells in less than or equal to 4 days of apheresis. Started Nov 2014; status: completed.
02
Drugs
plerixafor
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02221492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221492.